# Crinetics Pharmaceuticals Inc. (CRNX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $84.95, market value $9.0 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Crinetics Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 213.8×**. Each dollar of revenue is priced at 213.8×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 7.5×**. The shares trade at 7.5× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -4.7%** (5-yr avg -8.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -46.9%**. Return on equity is negative because earnings are negative.
- **Return on assets: -44.5%**. Each dollar of assets produces -44.5% of profit.

## Growth
- **Revenue growth (1 yr): 640.7%** (5-yr 155.3%/yr). Revenue grew 640.7% over the last year, against 155.3% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -34.1%**. Earnings per share fell 34.1%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 12.32** (quick 12.32). Current assets cover the next year's liabilities 12.32 times.
- **Altman Z-score: 41.06**. A Z-score of 41.06 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Crinetics Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: hold** (10 analysts). 10 analysts cover Crinetics Pharmaceuticals Inc.; the consensus is hold, with an average price target of $85.50 (+1% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 174.1%** (YTD 82.5%, 3-mo 146.1%). The shares are up 174.1% over twelve months including dividends.
- **From 52-week high: -0.1%** (163.0% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 90**. An RSI of 90 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 0.52** (volatility 113%). Beta of 0.52 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CRNX · Page: https://foliofundamentals.com/stocks/crnx

Not investment advice.